Form 4: Macrogenics CEO Exercises RSUs, Sells Shares for Tax

Macrogenics President and CEO Eric Risser exercised restricted stock units and subsequently sold a portion of the acquired shares to cover tax obligations.

Summary

• Eric Blasius Risser, President and CEO of Macrogenics Inc. (MGNX), reported transactions involving the company's common stock and restricted stock units (RSUs).
• On February 7, 2026, Risser acquired 6,668 shares of common stock through the conversion of restricted stock units.
• Concurrently on February 7, 2026, Risser disposed of 2,575 shares of common stock at a price of $1.81 per share to satisfy tax withholding obligations related to the RSU vesting.
• On February 8, 2026, Risser acquired an additional 11,166 shares of common stock from the conversion of restricted stock units.
• Also on February 8, 2026, Risser disposed of 4,311 shares of common stock at a price of $1.81 per share for tax withholding purposes.
• Following these transactions, Risser's direct beneficial ownership of common stock stands at 66,937 shares.
• After the February 7, 2026 conversion, 13,332 restricted stock units from a February 7, 2025 grant remain.
• After the February 8, 2026 conversion, 11,166 restricted stock units from a February 8, 2024 grant remain.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there is a sale of shares, it is for tax purposes related to the vesting of equity awards, which is a routine and expected occurrence. The underlying exercise of RSUs indicates the executive is realizing value from their compensation.

Positives

• The exercise of restricted stock units indicates a planned conversion of equity compensation, which is a routine part of executive compensation.
• The transactions are part of a Rule 10b5-1 plan, suggesting pre-planned and automated transactions rather than discretionary selling based on new information.

Negatives

• A portion of the acquired shares was sold to cover tax liabilities, which reduces the insider's direct ownership of common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to the vesting and exercise of equity awards, are common across all industries. The sale of shares to cover tax obligations upon vesting is a standard practice and typically does not reflect a change in management's outlook on the company's future.

Comparison to Industry Standards

• The practice of executives receiving restricted stock units as part of their compensation package is a standard industry practice, aligning executive incentives with shareholder value over the long term.
• The use of Rule 10b5-1 plans for pre-scheduled transactions, including tax-related sales, is a common corporate governance practice designed to mitigate concerns about insider trading.

Stakeholder Impact

• Shareholders: The conversion of RSUs results in a minor increase in the outstanding share count, but the transactions are routine and part of executive compensation, generally not impacting company strategy or operations.
• Employees: The transactions reflect standard equity compensation practices for executives.

Next Steps

• Future vesting installments of the remaining 13,332 restricted stock units from the February 7, 2025 grant.
• Future vesting installments of the remaining 11,166 restricted stock units from the February 8, 2024 grant.

Key Dates

Recommendation

The filing details routine insider transactions related to the vesting of restricted stock units and subsequent sales for tax purposes. These are expected events and do not provide new material information that would significantly alter the investment thesis for Macrogenics. Therefore, a 'hold' recommendation is appropriate as these transactions do not signal a strong buy or sell opportunity based on new fundamental insights.

Keywords

Macrogenics, MGNX, Eric Risser, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Tax Withholding, Rule 10b5-1